| Active Not Recruiting | TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer NCT03680508 | University of Hawaii | Phase 2 |
| Unknown | Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TAC NCT02557503 | Zhu Xu | Phase 4 |
| Completed | Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer NCT01666756 | City of Hope Medical Center | Phase 1 |
| Completed | PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Ca NCT02088775 | Fox Chase Cancer Center | N/A |
| Terminated | 3-Tesla MRI Response to TACE in HCC (Liver Cancer) NCT02057874 | Vanderbilt-Ingram Cancer Center | N/A |
| Active Not Recruiting | Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT NCT02119065 | University of Cincinnati | — |
| Completed | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery NCT01766219 | Wake Forest University Health Sciences | Phase 1 / Phase 2 |
| Completed | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer NCT01730937 | Radiation Therapy Oncology Group | Phase 3 |
| Withdrawn | Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duc NCT01859182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499 | University of Chicago | Phase 1 |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery NCT02072356 | Ohio State University Comprehensive Cancer Center | EARLY_Phase 1 |
| Terminated | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers NCT01229111 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant NCT01194206 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer NCT00427973 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant NCT00844168 | University of Washington | Phase 1 |
| Terminated | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer NCT00787787 | University of Washington | Phase 2 |
| Completed | IMC-A12 in Treating Patients With Advanced Liver Cancer NCT00639509 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer NCT00604721 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery NCT00459108 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer NCT00365391 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery NCT00321594 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer NCT00238394 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer NCT00107536 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) NCT00077441 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot B NCT00101036 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer NCT00083226 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) NCT00071994 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Du NCT00085410 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin in Treating Patients With Liver Cancer NCT00052364 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction NCT00047346 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed NCT00047333 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer NCT00033462 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer NCT00023946 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Remov NCT00006016 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |